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Abstract
Background: The rising incidence of pulmonary Mycobacterium avium-intracellulare complex (MAI) infection is
unexplained but parallels the growing world-wide epidemic of allergic disease. We hypothesized an association
between pulmonary MAI infection and Th2-type immune responses as seen in allergy.
Methods: Biomarkers of patient Th2-type immune responses (peripheral blood eosinophil counts and serum IgE
levels) were compared between patients with positive pulmonary samples for tuberculosis and non-tuberculous
mycobacterial (NTM) infection. A further comparison of clinical characteristics, including respiratory co-morbidities,
and biomarkers, was conducted between patients culturing MAI NTM and those culturing NTM other than MAI.
Results: Patients culturing NTM from pulmonary samples had significantly higher peripheral blood eosinophil levels
than those culturing Mycobacterium tuberculosis. Furthermore, patients culturing MAI compared to those culturing
NTM other than MAI had higher eosinophil counts (mean 0.29x109/L vs 0.15x109/L, p = 0.010) and IgE levels (geometric
mean 138kU/L vs 47kU/L, p = 0.021). However there was no significant difference in the frequency of asthma between
the two NTM groups.
Conclusions: There is an association between biomarkers of Th2-type immune responses and pulmonary MAI.
Prospective and translational research could identify the direction of causation; and so determine whether our finding
may be utilized within future management strategies for MAI.
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Background
The incidence of non-tuberculous mycobacterial
(NTM) infection is rising [1], and this appears to be
driven largely by an increase in pulmonary Mycobacter-
ium avium-intracellulare complex (MAI) infection [2].
Pulmonary NTM disease is characterized by respiratory
and constitutional symptoms, with significant impact
on quality of life [3, 4]. Treatment requires long-
courses of antibiotics, which often do not eradicate the
mycobacteria [5]. Furthermore, many of the antimicrobials
used to treat NTM disease have significant adverse-effects
and drug-drug interactions [6]. As a result, often the bene-
fit of attempting to treat localized infection is outweighed
by its complications - leaving patients with persistent
symptoms. Investigating the aetiology of pulmonary NTM
infections may therefore enable us to devise more effective
treatments and so manage the increasing number of af-
fected individuals.
Whilst disseminated NTM infections are associated
with severe immunodeficiency states such as HIV infec-
tion or defects in interferon gamma (IFNγ) and STAT3
pathways [7], the pathophysiology of localised pulmon-
ary NTM infection is unclear [8]. Pulmonary NTM dis-
ease is most often seen in patients with chronic
respiratory illness but this is perhaps confounded by
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doctors most often testing for NTM in such popula-
tions. Research in patients with cystic fibrosis demon-
strates a specific association between NTM infection
and allergic-bronchopulmonary aspergillosis (ABPA)
[9] - suggesting that the increased predilection for
NTM infections in patients with chronic lung disease is
more complex than simply mycobacteria thriving in
damaged lungs [10, 11].
In parallel with the increasing incidence of pulmon-
ary NTM disease over the last decades, there is a glo-
bally rising prevalence of allergic diseases and the
“atopic march” by which patients sequentially develop
eczema, food allergies, allergic rhinitis and eosino-
philic asthma [12, 13]. Dysregulated Th2 (T-helper
lymphocyte type 2) immune responses are thought to
underlie these states [14, 15]. Asthma itself is associ-
ated with increased susceptibility to, and severity of,
certain infections, and this appears to be independent
of the effect of corticosteroids [16]. For example,
Kloepfer and colleagues have shown asthmatic chil-
dren to be at greater risk of influenza infection [17],
whilst Talbot and colleagues have demonstrated an
association between asthma and invasive pneumococ-
cal disease [18]. Furthermore, Th2-type inflammation
is known to be associated with dissemination and im-
paired clearance of Cryptococcus [19, 20] and Histo-
plasma infections [21].
Following the observation in our NTM clinic of
several patients with eosinophilia, we hypothesised
that the increasing incidence of MAI disease reflects
an increase in allergic disease, with a direct associ-
ation between Th2-type cytokine predominant im-
mune responses and MAI infection. Therefore, we
reviewed biomarkers of Th2-type inflammation – per-
ipheral blood eosinophil counts and serum Immuno-
globulin E (IgE) levels [22] – in pulmonary NTM
patients and compared them, where available, to a
pulmonary tuberculosis cohort attending over the
same period.
Methods
Patient Groups
A complete list of all patients with positive mycobac-
terial cultures from pulmonary samples at the Royal
Free Hospital, London, UK, over the five years August
2010 – August 2015 was generated from the micro-
biology information system. Patients with known HIV,
current haematological malignancy or significant pri-
mary immunodeficiency condition were excluded. Our
NTM cohort was defined as those with at least two
positive mycobacterial cultures, at least one identified
NTM cultured and no positive cultures of Mycobac-
terium tuberculosis complex organisms. A cohort of
patients with culture-positive pulmonary tuberculosis
(TB) was similarly identified.
Patients’ pathology records were interrogated for the
preceding eosinophil count (as an absolute value and as
a percentage of the total white cell count) and total IgE
before and closest to the date of the first positive myco-
bacterial culture. If these were not available then the
first succeeding counts were recorded. A raised periph-
eral blood eosinophil count was defined as >0.4x109/L
and a raised serum IgE level as >150kU/L. An eosino-
phil count cut-off of 0.27x109/L was also evaluated,
given research showing this has a good sensitivity and
specificity for detection of active eosinophilic airway in-
flammation in asthmatic patients [23].
Electronic records of clinical correspondence con-
temporaneous to the first positive NTM sample were
also reviewed for evidence of patient or doctor reported
co-morbid diagnoses such as asthma.
Sample Analysis
Samples for mycobacterial analysis were received in sterile
containers, homogenized and centrifuged as appropriate
and decontaminated using NALC-NaOH method. All
specimens were inoculated into growth indicators tubes
(BD MGIT; BD, US), using 0.5 ml of processed specimen.
Specimens that flagged positive on the BD MGIT system
were examined for acid-fast bacilli and sub-cultured onto
pH neutral pyruvate-based Löwenstein Jensen slope. For
each patient with NTM the first two positive specimens
were sent to the Public Health England (PHE) Mycobac-
terial Reference Laboratory for identification; thereafter
new positive samples were sent monthly. The reference la-
boratory performed a Genotype Mycobacterium CM VER
2.0 analysis (Hain Lifescience, Germany).
Complete blood counts, including total white cell
counts and eosinophil counts, were assayed using Sys-
mex XN-9000 analyzers (Sysmex, Japan). Total IgE
measurement was performed on an ImmunoCAP 250
analyzer (ThermoScientific, US) using a fluorescence en-
zyme immunoassay technique (FEIA).
Statistics
GraphPad Prism 6.0 (GraphPad Software, USA) was
used for all parametric and non-parametric statistical
tests. Unpaired t-tests were used to compare mean
absolute eosinophil counts and mean percentage of
total leukocyte counts between patient groups, and to
compare IgE concentrations after logarithmic trans-
formation of the variable. Chi-squared tests were used
to compare distributions between patient groups of
eosinophil counts in the ranges <0.27x109/L vs 0.27-
0.4x109/L vs >0.4x109/L. For comparisons of subject
demographics between groups Chi-squared tests were
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employed (except for age in which an unpaired t-test
was used). Figures show mean and standard deviation
for all data except logarithmically transformed IgE
concentrations for which geometric mean and 95%
confidence interval are shown.
Results
Peripheral blood eosinophil counts are higher in patients
with NTM infection than in patients with tuberculosis
Ninety-three patients cultured pulmonary NTM with at
least two positive mycobacterial cultures over the five-
year period. 19 were excluded from further analysis as
they had known immunosuppressed states. Of the
remaining 74 patients, 26 had two or more different spe-
cies of NTM positively isolated in their cultures. Over
the same period 55 patients had culture-positive pul-
monary TB.
Peripheral blood eosinophil counts were significantly
higher in the NTM cohort than in patients with pulmon-
ary TB (mean 0.22x109/L vs 0.15x109/L, p = 0.049; Fig. 1a).
13 (18%) of NTM patients had an eosinophilia of
>0.4x109/L, with 19 (26%) a peripheral blood eosinophil
count of ≥0.27x109/L. This compared to only 2 (4%) of TB
patients with an eosinophilia of >0.4x109/L and 10 (18%)
with a count ≥0.27x109/L (p = 0.035, Chi-squared test).
Of the patients with NTM infection, 11 had a raised
serum IgE >150kU/L out of 36 patients with a measured
level (Fig. 1b). Although eosinophil and IgE levels were
both elevated in some NTM patients (5 with eosinophil
counts > 0.4x109/L and total IgE >150 kU/L), others only
had one or other raised (Fig. 1c). Serum IgE had only
been assessed in one TB patient and therefore serum IgE
levels could not be meaningfully compared between the
TB patients and NTM patients.
Prevalence of asthma is similar in patients culturing MAI
complex mycobacterium and those culturing only other
NTM
Given our hypothesis of an association between Th2 in-
flammation and MAI infection in particular, we next
analyzed our NTM patient cohort by separating the pa-
tients into those culturing MAI complex mycobacteria
as opposed to those culturing only NTM other than
MAI complex mycobacteria. 36 (49%) individuals cul-
tured MAI amongst their NTM isolates whilst in 38 only
NTM other than MAI were identified. The ages of
patients in both groups were not significantly different
with mean (standard deviation) age of 63.3 years (16.43)
for patients culturing MAI and 64.4 (15.36) for patients
with NTM other than MAI. Similarly the gender distri-
bution of patients was similar for both NTM groups
(Table 1). The proportion of patients with different re-
spiratory co-morbidities was comparable in people with
MAI and those culturing only other NTM. In particular,
proportions were similar for asthma (6 of 36 vs 4 of 38;
p = 0.44, Chi-squared test) and COPD (9 of 36 vs 15 of
38; p = 0.18). However bronchiectasis was more common
in the MAI group (15 of 36 vs 5 of 38; p = 0.006). Only
one patient had a diagnosis of ABPA, and they had cul-
tured MAI. Usage of inhaled corticosteroids was similar
between the two groups (19 of 36 vs 15 of 38; p = 0.25).
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Fig. 1 Peripheral blood eosinophil counts and serum IgE levels for patients culturing Mycobacterium tuberculosis and non-tuberculous mycobacteria.
a Peripheral blood eosinophil counts of patients culturing non-tuberculous mycobacteria (NTM), n = 74, and M tuberculosis complex (TB), n = 55. Dotted
lines at counts of 0.27x109/L and 0.4x109/L. Un-paired t-test with Welch’s correction; *, p≤ 0.05. b Serum IgE levels for NTM patients, n = 36. Dotted line
at 150kU/L. c Serum IgE levels plotted versus peripheral blood eosinophil counts for NTM patients
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Eosinophil counts and serum IgE levels are highest in
patients culturing Mycobacterium avium-intracellulare
(MAI) complex NTM
We next addressed whether biomarkers of Th2 inflam-
mation are particularly elevated in patients with MAI
complex mycobacteria compared to other NTM. A high
proportion of patients who had cultured M avium (8 of
26 patients) or M intracellulare (6 of 16) had an eosino-
philia >0.4x109/L (Fig. 2a). Similarly a high proportion of
patients culturing either of these species of Mycobacter-
ium had elevated IgE levels (Fig. 2b).
Peripheral blood eosinophils, either as an absolute
count or as a percentage of the total leukocyte count,
were significantly higher in patients culturing MAI com-
plex compared to patients who had cultured NTM but
no MAI organisms (mean 0.29x109/L vs 0.15x109/L, p =
0.010, and 3.5% vs 2.1%, p = 0.036; Fig. 3a-b).
After exclusion of an outlier with IgE >5000kU/L,
serum IgE levels were significantly higher in individuals
who had cultured MAI than in those only culturing
other NTM (geometric mean 138kU/L vs 47kU/L, p =
0.021; Fig. 3c). Aspergillus specific IgE was measured in
a small number of patients and could not be compared
between NTM groups.
Characteristics of eosinophilic patients with NTM infection
To examine whether there were particular characteristics
associated with eosinophilic NTM infection, we exam-
ined this subgroup of 13 patients with peripheral blood
eosinophil count >0.4x109/L in further detail. The aver-
age age of these patients at the time of producing the
NTM-cultured sample was 63 years. 8 were female and
5 male. 10 of the patients had cultured MAI complex
NTM and 3 only other NTM. The mean IgE level was
948kU/L (measured in 9 patients). The 13 patients in-
cluded the one patient with diagnosed ABPA and two
further patients who had significantly raised Aspergillus
specific IgE. All three cultured either M. avium or M.
intracellulare. A further two had Aspergillus specific IgE
within the normal range. 4 of the 13 eosinophilic pa-
tients had been diagnosed with asthma, including the 3
patients with the highest peripheral blood eosinophil
counts – they had cultured either M. avium or M. intra-
cellulare whereas the fourth asthmatic patient had cul-
tured M. xenopi. All of the 4 asthmatic patients and 5
others were using inhaled corticosteroids.
CT thorax imaging was available for 12 of these 13 pa-
tients. Abnormalities on thoracic imaging were present
in all of them. Tree-in-bud changes were evident in 3
patients and less defined/more widespread nodularity in
a further 4. Airway changes on the bronchiectatic
spectrum were present in 7. Upper lobe fibrosis with
cavitation was found in 1 patient and a right upper lobe
cavity evident in another.
Discussion
Over recent decades there has been a rising incidence of
both NTM infection, driven by increasing MAI infec-
tions, and atopic/allergic diseases, with the latter under-
pinned by Th2-type immune responses [1, 2, 12, 13].
We therefore hypothesized a possible association be-
tween MAI infection and Th2-type immune responses
and investigated our cohort of patients with mycobacter-
ial infection to evaluate this, using blood eosinophil
count and serum IgE biomarkers of Th2-type responses.
In the absence of a hematological malignancy, the Th2-
type cytokine interleukin-5 (IL-5) is critical for the de-
velopment of a peripheral eosinophilia [24] whilst B
lymphocyte class-switching to IgE synthesis is dependent
on the Th2-type cytokines IL-4/IL-13 [25]. We found
significantly higher peripheral blood eosinophil counts
in patients with NTM infection compared to pulmonary
Table 1 Demographics, respiratory co-morbidities and corticosteroid usage in NTM patients
Patients with MAI complex NTM Patients with NTM only other than MAI
Total Subjects 36 38
Mean Age/yrs (standard error of mean; range) 63.3 (2.74; 22.6 – 88.7) 64.4 (2.49; 31.3 – 90.3) p = 0.78
Sex 22 female, 14 male 17 female, 21 male p = 0.16
Subjects culturing multiple NTM species 18 (50%) 8 (21%) p = 0.009
Asthma 6 (17%) 4 (11%) p = 0.44
COPD 9 (25%) 15 (39%) p = 0.18
Bronchiectasis 15 (42%) 5 (13%) p = 0.006
ABPA 1 (3%) 0 (0%) p = 0.30
Nasal Polyps 2 (6%) 1 (3%) p = 0.52
on Inhaled Corticosteroids 19 (53%) 15 (39%) p = 0.25
on Oral Corticosteroids 3 (8%) 3 (8%) p = 0.94
Respiratory co-morbidities and usage of inhaled/oral corticosteroids in patients in our NTM cohort as detailed in medical notes contemporary to the dates of their
first isolated NTM. Values represent number (%) except where specified
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Fig. 3 Eosinophil counts and serum IgE levels are significantly higher in patients culturing MAI complex mycobacterium than in patients only
culturing other species of NTM. a-c Peripheral blood eosinophil counts, eosinophils as a percentage of the total leukocyte count, and serum IgE
levels compared between patients whose samples cultured a Mycobacterium avium-intracellulare (MAI) complex NTM and those patients who
cultured NTM only other than MAI mycobacteria. Unpaired t-tests with Welch’s correction (in the case of IgE levels after logarithmic transformation
and exclusion of outlier indicated by symbol X); *, p≤ 0.05
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Fig. 2 Eosinophil counts and serum IgE levels associated with different species of non-tuberculous mycobacteria. a Peripheral blood eosinophil
counts and b serum IgE levels of patients culturing different species of NTM
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TB; and significantly higher eosinophil counts and
serum IgE levels in patients culturing MAI complex
NTM compared to those culturing only NTM other
than MAI. Given the sample size in this study, the statis-
tical significance of these differences is notable. We did
not find asthma to be a more frequent co-morbidity in
patients culturing MAI; however, not all cases of asthma
are necessarily underpinned by allergic mechanisms or
Th2-type inflammation [26]. Bronchiectasis was more
common in patients culturing MAI NTM, and is of
some interest given recent research regarding the associ-
ation between NTM disease and bronchiectasis [27], and
the frequency in asthma of airway changes along the
bronchiectatic spectrum [28].
The association between MAI infection and Th2-type
inflammation, as indicated by raised peripheral blood eo-
sinophil levels and serum IgE levels, could have several ex-
planations. One possibility is that inhaled corticosteroids
used to treat Th2-associated airway inflammation (eg
asthma, ABPA and eosinophilic COPD) may underlie the
association. Previous studies have suggested steroids are a
risk factor for NTM disease [9, 10]. If this were the
explanation then it is of concern, as peripheral blood
eosinophilia is increasingly regarded as a biomarker of
under-treated steroid-responsive airways inflammation
that requires increased steroid doses [23, 29] - which
might paradoxically further increase the risk of NTM dis-
ease and impair anti-mycobacterial immune responses.
Alternatively, Th2-type inflammation itself could pre-
dispose to MAI infection. Successful host defense
against mycobacteria with clearance/control of mycobac-
terial infection requires an effective Th1, and to lesser
extent functioning Th17, immunological response rather
than a Th2-type response [30, 31]. These different facets
of the adaptive immune system are capable of cross-
regulation – which allows an acute immune response to
be specifically optimized to the character of any infec-
tion. However (chronic) disequilibrium between the dif-
ferent divisions of the adaptive immune system may lead
to pathology and susceptibility to infection [32].
Mediators of Th2-type inflammation in allergic disease
may suppress anti-mycobacterial responses in patients
leading to persisting NTM infection. For example, the
Th2-type cytokine IL-4 is known to inhibit Th1 and
Th17 responses [33, 34]. Such mechanisms are thought
to underlie the diminished IFN responses and more se-
vere pathology seen in respiratory viral infections in
asthmatics [35]. IL-5 also has the capacity to impair IFN
responses [36]. If this were the case then suppressing
Th2-type inflammation may be beneficial in MAI infec-
tion. For example, it is possible that anti-Th2 cytokine
monoclonal antibody therapy could be a useful compo-
nent of treatment for MAI, optimizing the body’s own
anti-mycobacterial immune responses. It is notable that
patients with common variable immune deficiency
(CVID) and X-linked agammaglobulinaemia (XLA), who
are unable to generate IgE, only rarely seem to develop
NTM infections despite their increased susceptibility to
other organisms and a very high incidence of bronchiec-
tasis ([37, 38] and unpublished observations).
Finally, it is possible that MAI complex mycobacteria
have developed defensive mechanisms to skew immune
responses towards a Th2-type bias that decreases the
ability of the immune system to clear the mycobacteria.
For example, Francisella tularensis has previously been
shown to promote macrophage differentiation into an
‘alternatively activated’ phenotype, more associated with
allergic disease and tissue repair/remodeling than killing
of intracellular pathogens [39].
There is a growing research field investigating the pul-
monary microbiome in airway diseases: a prevailing the-
ory is that loss of microbial diversity in patients with
asthma may be responsible for dysregulated pulmonary
immune tolerance and onset of disease pathology [40].
However, there is now increasing interest in the mecha-
nisms by which respiratory microbes may perturb pul-
monary immune responses and in particular how
epithelial stimulation from microbial proteases may elicit
Th2-type inflammation, with production of IL-4, IL-5
and IL-13 (for example) by other cells of the immune
system such as innate lymphoid cells [41, 42].
Hence, there are several possible mechanisms by which
MAI infection could directly promote aberrant pulmonary
Th2-type inflammation. Interestingly, Fritscher and col-
leagues have reported a case-series of difficult-to-control
asthma patients found to have NTM infection, the major-
ity of whom had Mycobacterium avium complex infection
[43]. In most of the patients treated with anti-
mycobacterial therapy there was an improvement in their
symptomatology.
A limitation of our work is that patient data were col-
lected retrospectively. Therefore information on preva-
lence of eczema, food allergies and allergic rhinitis (the
other diseases of the atopic march) was not available for
most of these patients. Furthermore, the basis of asthma
diagnoses in this cohort, whether patients had diagnostic
lung function studies, and fractional exhaled nitric oxide
(FeNO) measures of Th2-associated airway inflamma-
tion were not included in the available patient data.
Additionally our eosinophilic patients were not univer-
sally screened for possible helminth infections that could
potentially underlie the peripheral blood eosinophilia
seen in these individuals (which is important given the
current research interest into impaired anti-mycobacterial
immune responses in patients with helminth and TB co-
infections [44]). However the prevalence of helminth in-
fection in London, UK, is very low and allergic/atopic
disease is the cause of most peripheral blood eosinophilia
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in developed countries [45]. Further prospective research
is needed to better investigate these observations, and on
the basis of these results we would therefore advise that
future studies of risk-factors for NTM disease should rec-
ord whether patients have allergic/atopic co-morbidities,
including aero-allergen testing, and include markers of
Th2-type inflammation.
Conclusions
We have shown an association between biomarkers of
Th2-type immune responses and MAI complex NTM
infection. It is possible that the developing epidemic of
allergic/atopic disease may in part explain the increasing
incidence of NTM infection – though the direction of
causality remains undefined.
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